Scott P. Kennedy work email
- Valid
- Valid
Scott P. Kennedy personal email
Results-driven executive leader with a track record of applying breakthrough science to the discovery and development of novel small molecule and biological therapeutics. Global experience in managing a portfolio of internal drug discovery programs and external alliances to consistently deliver on company productivity and quality goals. Proven ability to:Build innovative and effective teamsLead in a matrix environment across multiple therapeutic, technology and discipline areas by establishing a high level of credibility and personal integrityDeliver and advance a portfolio of programs into late clinical development against significant challengesEstablish external strategic academic and biotechnology alliances to maximize portfolio valueLead organizational and cultural change across internal and external interfaces by developing and leveraging relationshipsDevelop and motivate talented leaders
Self-Employed
-
Retired - Vp, Global Head, Translational Medicine Biomarker Development, NibrSelf-Employed Sep 2023 - PresentI have had a wonderful scientific, medical and leadership career journey through academic and 31 years of biotech and pharmaceutical opportunities. My consistent engagement was based on learning something new every day, ensuring I added value and impact, and getting to partner with many intelligent associates. Thank you and always happy to chat and discuss topics that are important to you, so just reach out thru Linked In. Gotta go fishing now !
-
Vice President, Global Head Of Biomarker Development, Translational MedicineNovartis Institute For Biomedical Research Jul 2010 - Sep 2023Basel, Baselstadt, ChMy role provides strategic, technical and innovative leadership to a diverse portfolio of >100 translational research and clinical studies; engages a network of external partners that support a comprehensive range of biomarker disciplines (molecular, genetic, cellular, imaging, digital devices, data sciences) and represents Novartis on various internal and external scientific, technical, and advisory organizations; provides organizational leadership for groups in EU, US and Asia and local Cambridge Translational Medicine site. -
Chief Scientific OfficerRaindance Technologies Nov 2009 - Mar 2010Billerica, Ma, Us-Led strategy development for the microdroplet single cell genomic analysis and biomarker platform-Led business development strategic partnership discussions in screening and clinical testing -Developed publication and technical marketing strategies for targeted sequence enrichment-Presented as the company’s “external voice” in academic, biotechnology, and pharma sectors -
FounderFish Doc Biopharma Consulting Llc Dec 2008 - Oct 2009Consulted on science, priorities, key milestone delivery to proof of concept and business plans for technology portfolio biotechnology companiesConsulted on science and drug discovery/development path to proof of concept for multiple biotechnology start-up companies
-
Head East Region Ww Exploratory Science And TechnologyPfizer Inc Jun 2007 - Nov 2008UsFacilitated and guided multi-million dollar investment into creation of new Biotechnology ventures (technology and products) as sole Pfizer board member of Boston BioCom LLCEnabled and improved relationships and access to key Academic Medical Centers by completing a broad alliance agreement with UPennWorked closely with senior therapeutic area leaders to implement external strategic scientific imperatives for Pfizer R&D/Canada with focus on cardiovascular and metabolic disease, neuroscience and antibacterials therapeutic areas -
Vice PresidentPfizer Inc Nov 2003 - Jun 2007UsDesigned and implemented an innovative Global Development and Regulatory submissions/Centers of Emphasis organization ($70 M budget, 357 FTEs), across eight sites/4four countries, including an outsourcing strategyEnsured consistent and efficient risk assessment planning and regulatory filings for a broad portfolio of programs (from IND through supplemental NDA) including antibacterials, Cardiovascular/Metabolic disease, Immunology/Cancer, and NeurosciencesEstablished novel discovery based safety screening paradigms (genetic/reproductive/general toxicology, and safety pharmacology) which has reduced program attrition in the pre-IND phaseChampioned global safety data sharing effort which included integrating regulatory and discovery cultures as well as partnering with informatics/Quality Assurance leadership to create a platform capable of capturing varied data types
-
Executive DirectorPfizer Inc Apr 2001 - Nov 2003New York, New York, UsManaged all aspects of Zone biology/pharmacology/molecular sciences deployment, and program/portfolio strategy as well as a Discovery Electron Microscopy and Antibody, Cellular and Molecular Interactions FacilityDelivered high quality pre-clinical candidates/yr across three therapeutic areas and multiple target families including chemokine receptors, kinases, prostaglandin receptors/enzymes, nuclear hormone receptors, and proteasesAdvanced multiple candidates into Phase one clinical studies for immunology/inflammatory/infectious diseases (rheumatoid arthritis, psoriasis, transplantation, osteoarthritis, multiple sclerosis, immunotherapy for cancer, asthma/COPD, antibacterials) and two chemokine receptor therapeutic agents for rheumatoid arthritis (and later multiple sclerosis) through Phase two clinical studiesManaged external Strategic Alliance Collaborations to deliver on goals and impact portfolio progression -
Assistant DirectorPfizer Inc Oct 1998 - Apr 2001UsImplemented target identification, validation, technology integration, screen assay development and exploratory research in Respiratory, Allergy, Immunology, Inflammation and Infectious DiseasesChampioned Pfizer’s first cohort of human monoclonal therapeutic antibody candidatesManaged External Grants Budget and External Technology Collaborations for the zonePioneered a cross-discipline/line technology team for prioritization and advancement of early drug targets through the exploratory phases which was adopted as a PGRD stage-gate guideline best practice and led to a consistent and enhanced delivery of projects into late stage discovery
-
Senior Research InvestigatorPfizer Inc Feb 1994 - Oct 1998UsLab head in Metabolic Disease and Cardiovascular Zone (CV) and head of Tissue Culture Lab
-
Staff ScientistAlexion Aug 1992 - Feb 1994Boston, Massachusetts, UsLab Head in Cardiovascula Biology Group -
Senior ScientistAlexion Pharmaceuticals 1992 - 1994
Scott P. Kennedy Skills
Scott P. Kennedy Education Details
-
The University Of Connecticut Health CenterImmunology -
Trinity College-HartfordBiochemistry
Frequently Asked Questions about Scott P. Kennedy
What company does Scott P. Kennedy work for?
Scott P. Kennedy works for Self-Employed
What is Scott P. Kennedy's role at the current company?
Scott P. Kennedy's current role is Retired: Global Head Biomarker Development, Translational Medicine Cambridge Site Head, NIBR.
What is Scott P. Kennedy's email address?
Scott P. Kennedy's email address is sp****@****ast.net
What schools did Scott P. Kennedy attend?
Scott P. Kennedy attended The University Of Connecticut Health Center, Trinity College-Hartford.
What skills is Scott P. Kennedy known for?
Scott P. Kennedy has skills like Drug Discovery, Biotechnology, Clinical Development, Biomarkers, Life Sciences, Drug Development, Immunology, Lifesciences, Clinical Trials, Infectious Diseases, Assay Development, Translational Medicine.
Free Chrome Extension
Find emails, phones & company data instantly
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial